Epis 2017

2017-10-17T16:05:02+00:0016/10/2017|Categories: Events|Tags: , |

Welcome to the 2nd European Patient Innovation Summit (EPIS 2017) – Realising the connection of digital technologies. Building upon the success and key learnings of the inaugural 2016 Summit, Novartis has continued to collaborate closely with a number of Europe’s leading patient organisations in order to deliver this year’s event. Using the latest digital technologies, the Summit aims to bring together patient organisations representing chronic disease communities at both a national and European level. EPIS 2017 will feature an innovative multisite format, with regional hubs in France, Germany, Italy, Norway, Portugal and Spain, and a Central Hub in Dublin, Ireland. The [...]

Novartis announces AMG 334 significantly reduces patients’ monthly migraine days in phase II study of chronic migraine prevention

2017-08-10T15:32:49+00:0010/08/2017|Categories: Industry|Tags: , |

Phase II 20120295 study of AMG 334 met primary endpoint, confirming efficacy and safety in patients with chronic migraine over 12 weeks of treatment Migraine is a leading cause of disability, affecting more than 10% of people worldwide – within the overall migraine population, people with chronic migraine experience the greatest impact on daily activities and quality of life AMG 334 is being co-developed by Novartis and Amgen 
Basel, 8 June 2016 – Novartis today announced positive first results from the global phase II 20120295 study, investigating the efficacy and safety of the fully human monoclonal antibody AMG 334 (erenumab) [...]

We and our partners use cookies, to collect browsing data to give you the best online experience and to personalize the content, play multimedia content, interact with social networks and perform browsing analytics. If you continue browsing we understand you accept the use of such technology. For more information visit our cookies policy Find out more

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.